Hyman DM, Willis T, Kummar S, et al. The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers. J Clin Oncol 35, 2017 (suppl; abstr LBA2501).
Effect van doseringsregime RTS,S/AS01-vaccin en baseline malaria-infectie op vaccineffectiviteit
mrt 2025 | Parasitaire infecties, Vaccinatie